共 751 条
- [1] Yazdanpanah F(2020)The immune system and COVID-19: Friend or foe? Life Sci. 256 117900-117900
- [2] Hamblin MR(2020)Immune response in COVID-19: Addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2 Signal Transduct Target Ther. 5 84-17
- [3] Rezaei N(2021)Immunopathology of hyperinflammation in COVID-19 Am. J. Pathol. 191 4-e261
- [4] Catanzaro M(2021)Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: A cohort study Lancet Rheumatol. 3 e253-704
- [5] Fagiani F(2021)Dexamethasone in hospitalized patients with Covid-19 N. Engl. J. Med. 384 693-631226
- [6] Racchi M(2021)Inflammation and antiviral immune response associated with severe progression of COVID-19 Front. Immunol. 12 631226-1659
- [7] Corsini E(2021)COVID-19 and toll-like receptor 4 (TLR4): SARS-CoV-2 may bind and activate TLR4 to increase ACE2 expression, facilitating entry and causing hyperinflammation Mediat. Inflamm. 2021 8874339-107233
- [8] Govoni S(2020)The beneficial and pathogenic roles of complement in COVID-19 Cleve Clin. J. Med. 51 1652-1440
- [9] Lanni C(2021)Complement cascade in severe forms of COVID-19: Recent advances in therapy Eur. J. Immunol. 2021 107233-329
- [10] Gustine JN(2021)Neutrophils and COVID-19: The road so far Int. Immunopharmacol. 18 206-872